Related Experiment Videos
Model for the molecular genetic diagnosis of endometrial cancer using K-ras mutation analysis
R M Al-Jehani1, A R Jeyarajah, B Hagen
1Department of Gynaecological Oncology, St. Bartholomew's Hospital, London, UK. R.ALJEHANI@mds.qmw.ac.uk
Journal of the National Cancer Institute
|April 16, 1998
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Setup of a Contamination Control Strategy Using the Hazard Analysis Critical Control Point (HACCP) Methodology.
PDA journal of pharmaceutical science and technology·2023
Association of hysterectomy and invasive epithelial ovarian and tubal cancer: a cohort study within UKCTOCS.
BJOG : an international journal of obstetrics and gynaecology·2021
Invasive cervical cancer in pregnancy.
Best practice & research. Clinical obstetrics & gynaecology·2015
SHBG as a breast cancer risk biomarker in premenopausal women? Results from an individual patient's pooled analysis and a meta-analysis.
Journal of the National Cancer Institute·2026
PRO‑CTCAE in Oncology Drug Evaluation: Cross-Agency Review of Regulatory and Health Technology Assessment Decision-Making in the United States and Europe.
Journal of the National Cancer Institute·2026
Endocrine Biomarker Changes in a Randomised Low-Dose Tamoxifen Trial for Breast Cancer Prevention.
Journal of the National Cancer Institute·2026
Treatment Effect Discrepancy Between PFS and OS in Antibody-Drug Conjugate Trials for Metastatic Breast Cancer: A Meta-Epidemiologic Analysis.
Journal of the National Cancer Institute·2026
Integrating genetic predictors into subsequent breast cancer risk prediction in survivors of childhood cancer.
Journal of the National Cancer Institute·2026
(Neo)adjuvant approvals for solid tumors by the US Food and Drug Administration 2010-2023.
Journal of the National Cancer Institute·2026
Hypoxia-Induced Expression of miR-424, miR-155, CD47, and PD-L1 in a Gastric Cancer Cell Line (MKN-45).
Iranian biomedical journal·2026
Long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced NSCLC: FLAURA2.
Lung cancer (Amsterdam, Netherlands)·2026